Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

ObjectiveIn the double-blind, phase III, placebo-controlled RUBY randomized clinical trial, dostarlimab plus carboplatin-paclitaxel significantly increased survival among patients with primary advanced or recurrent endometrial cancer (EC). We conducted a cost-effectiveness analysis of dostarlimab in...

Descripció completa

Dades bibliogràfiques
Autors principals:	Gengwei Huo, Ying Song, Wei Liu, Hua Guo, Peng Chen
Format:	Article
Idioma:	English
Publicat:	Frontiers Media S.A. 2024-06-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	dostarlimab endometrial cancer Markov model RUBY cost-effectiveness
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1391896/full

Ítems similars

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
per: Gengwei Huo, et al.
Publicat: (2023-02-01)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
per: Wenjie Liu, et al.
Publicat: (2023-07-01)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
per: Wenjie Liu, et al.
Publicat: (2024-02-01)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
per: Maojin You, et al.
Publicat: (2023-09-01)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
per: Michele Bartoletti, et al.
Publicat: (2022-07-01)

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
per: Wenjie Liu, et al.
Publicat: (2022-06-01)

Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features
per: Gengwei Huo, et al.
Publicat: (2022-04-01)

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
per: Gengwei Huo, et al.
Publicat: (2024-03-01)

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
per: Bujnak AC, et al.
Publicat: (2025-01-01)

Cost effectiveness of immunotherapy combination therapies for endometrial cancer
per: David J. Benjamin, et al.
Publicat: (2024-04-01)

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis
per: Gengwei Huo, et al.
Publicat: (2023-02-01)

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
per: Wenjie Liu, et al.
Publicat: (2023-05-01)

Oncogenic role of TWF2 in human tumors: A pan-cancer analysis
per: Liu Wenjie, et al.
Publicat: (2022-09-01)

A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)
per: Xiaolong Tom Zhang, et al.
Publicat: (2021-11-01)

Dostarlimab: From preclinical investigation to drug approval and future directions
per: Carlo Maria Cicala, et al.
Publicat: (2023-01-01)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
per: Sina Marzoughi, et al.
Publicat: (2021-12-01)

Dostarlimab: A Review
per: Bárbara Costa, et al.
Publicat: (2022-07-01)

<sup>18</sup>F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
per: Romain-David Seban, et al.
Publicat: (2021-07-01)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
per: Vanshikha Singh, et al.
Publicat: (2022-08-01)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
per: Tae-Jun Jeong, et al.
Publicat: (2022-12-01)

How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
per: Brigida Anna Maiorano, et al.
Publicat: (2022-04-01)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
per: Francesca Arezzo, et al.
Publicat: (2023-09-01)

Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
per: Francesca Arezzo, et al.
Publicat: (2024-01-01)

Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma
per: Sophia Gandarillas, et al.
Publicat: (2024-03-01)

An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker
per: Sitangshu Sekhar Biswas, et al.
Publicat: (2023-12-01)

The journey of dostarlimab: a successful weapon for cancer treatment
per: Rouchan Ali, et al.
Publicat: (2022-12-01)

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models
per: Sujatha Kumar, et al.
Publicat: (2021-01-01)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
per: Mingyang Feng, et al.
Publicat: (2022-05-01)

High incidence and reversible bradycardia events following alectinib initiation
per: Dongqi Yuan, et al.
Publicat: (2023-02-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
per: Wenwang Lang, et al.
Publicat: (2025-01-01)

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
per: Jiahao Zhang, et al.
Publicat: (2025-01-01)

Association between chemotherapy for surgically treated rectal cancer and second primary endometrial cancer
per: Tianyu Gao, et al.
Publicat: (2024-08-01)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
per: Meiyu Wu, et al.
Publicat: (2022-05-01)

Research on the Jiamusi Area’s Shallow Groundwater Recharge Using Remote Sensing and the SWAT Model
per: Xiao Yang, et al.
Publicat: (2024-08-01)

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy
per: Junyu Chen, et al.
Publicat: (2021-09-01)

Modification of activated carbon via grafting polyethyleneimine to remove amaranth from water
per: Likang Fu, et al.
Publicat: (2017-03-01)

Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
per: Peng-Fei Zhang, et al.
Publicat: (2023-09-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
per: Zhuo‐Miao Ye, et al.
Publicat: (2023-03-01)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
per: Zhiwei Zheng, et al.
Publicat: (2022-09-01)

Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer
per: Xiao Huo, et al.
Publicat: (2019-11-01)